Medical Progress Today
mpt home | sign up

Volume 2, Number 39
October 27, 2005


PRINTER FRIENDLY

In the Spotlight

The Lion and the Lambs Laying Down Together
Why the federal government shouldn't "negotiate drug prices"

Benjamin Zycher, Ph.D., Medical Progress Today, 10-27-05

Wal-Mart does it. Big pharmacy chains do it. Insurance companies and HMOs do it. And for all I know, the birds and the bees do it too.
Continue reading . . .

News

Drug companies warned on growth – IMS Health
Financial Times, 10-26-05

Editor’s Notes:

Aging populations in the U.S. and Europe are demanding access to a growing array of medicines for both chronic disabilities and the mundane ravages of aging. Affluent consumers in growing economies like India and China can be expected to develop the same tastes (and waistlines and dietary habits) in short order.
Continue reading . . .

Trial Lawyers Inc. Health Care:The Lawsuit Industry's Effect on American Health, 2005
Manhattan Institute, 10-26-05

Report: Rx drug sales to soar in U.S.
Associated Press Newswires, 10-25-05

Editor’s Notes:

This article looks at the growth in pharmaceutical spending with a focus on the U.S. The Associated Press reports:
Continue reading . . .

Warnings on SSRIs, ADHD Drug Should Not Discourage Appropriate Use
Medscape, 10-24-05

Editor’s Notes:

Psychiatrists are starting to voice some discomfort with last year’s backlash against some widely used drugs for treating depression and ADHD.
Continue reading . . .

Commentary

A Comparison of Propositions 78 and 79, Prescription Drug Pricing Initiatives in the November 8, 2005, Special Election
John R. Graham, Pacific Research Institute, 10-27-05

This report, from John Graham, director of health care studies at the Pacific Research Institute, examines the dueling prescription drug discount initiatives that will be featured in the upcoming (November 8) special election in California.
Continue reading . . .

May Reagan GOP R.I.P
Robert Goldberg, Ph.D., Washington Times, 10-26-05

Goldberg, a senior fellow at the Manhattan Institute’s Center for Medical Progress, argues against Congressional plans to finance budget savings by ill-considered changes to how Medicaid treats prescription drug spending:
Continue reading . . .

Values-Driven Healthcare: Freedom of Conscience for the Consumer
Robert E. Moffit, Ph.D., Heritage Foundation, 10-25-05

Moffit and his colleagues point out that we are rapidly approaching an era where medical technologies will vastly expand opportunities for patient choice, but that we are locked into an insurance system that places health care decisions largely in the hands of employers and government agencies rather than individuals.
Continue reading . . .

Healthy profits have healing powers
Benjamin Zycher, Ph.D., Los Angeles Times, 10-25-05

Zycher points out that while politicians are frantically scrambling to find treatments for a potentially devastating (but unlikely) avian flu pandemic, they have previously spent decades undermining the ability of pharmaceutical companies to provide vaccines and other treatments against emerging diseases and bioterror threats.
Continue reading . . .

U.S. Consumers Shafted by European Price Controls
James K. Glassman, Scripps Howard News Service, 10-25-05

Glassman reminds us that while the U.S. spends over twice as much per-capita on health care as other OECD (Organization for Economic Cooperation and Development) nations, the U.S. also pays a disproportionate share of the costs of developing new health care technologies because of price controls used by other developed nations.
Continue reading . . .

Florida's Medicaid Gamble
The New York Times, 10-24-05

The New York Times is not, as a rule, a proponent of business deregulation or market driven health care, but they certainly deserve a hat-tip for this editorial on the recent decision by the Department of Health and Human Services to grant Florida’s Medicaid program a waiver for wide-ranging consumer-driven reforms.
Continue reading . . .

Hot Topic: Political Virus
Wall Street Journal, 10-22-05

The Journal chronicles how the government has killed the goose that laid the vaccine golden-egg. Over the last few decades, price controls and liability-exposure, combined with onerous and expanded regulations at the FDA, have crippled the vaccine industry
Continue reading . . .


Medical Progress Today is published by the Center for Medical Progress at the Manhattan Institute for Policy Research.

For more information about Medical Progress Today, please contact the managing editor, Paul Howard, at phoward@manhattan-institute.org, or via telephone at 212.599.7000.

Press inquiries regarding Medical Progress Today can be directed to the Communications Department, at communications@manhattan-institute.org, or via telephone at 212.599.7000.

If you would like to unsubscribe, please reply to us and type "Unsubscribe" in the subject line.

In this week's issue:

SPOTLIGHT

The Lion and the Lambs Laying Down Together

NEWS

Drug companies warned on growth – IMS Health
Trial Lawyers Inc. Health Care:The Lawsuit Industry's Effect on American Health, 2005
Report: Rx drug sales to soar in U.S.
Warnings on SSRIs, ADHD Drug Should Not Discourage Appropriate Use

COMMENTARY

A Comparison of Propositions 78 and 79, Prescription Drug Pricing Initiatives in the November 8, 2005, Special Election
May Reagan GOP R.I.P
Values-Driven Healthcare: Freedom of Conscience for the Consumer
Healthy profits have healing powers
U.S. Consumers Shafted by European Price Controls
Florida's Medicaid Gamble
Hot Topic: Political Virus
Center for Medical Progress 
Copyright Manhattan Institute for Policy Research
52 Vanderbilt Avenue
New York, NY 10017
(212) 599-7000
mpt@manhattan-institute.org